Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
445.10
-0.90 (-0.20%)
At close: May 28, 2025, 4:00 PM
442.42
-2.68 (-0.60%)
After-hours: May 28, 2025, 5:26 PM EDT
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.29B 10.19B 9.81B 9.50B 9.29B 8.94B 8.63B 8.37B
Trikafta and Kaftrio Growth
10.80% 13.95% 13.59% 13.46% 15.77% 16.36% 17.33% 21.24%
Kalydeco
- - - - - 475.50M 499.20M 525.80M
Kalydeco Growth
- - - - - -14.05% -12.31% -11.23%
Orkambi
- - - - - 326.00M 392.60M 475.80M
Orkambi Growth
- - - - - -36.17% -28.27% -18.75%
Symdeko and Semkevi
- - - - - 123.00M 129.50M 134.30M
Symdeko and Semkevi Growth
- - - - - -31.67% -42.72% -50.13%
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
US
6.82B 6.68B 6.42B 6.26B 6.16B 6.04B 5.93B 5.83B
US Growth
10.75% 10.67% 8.37% 7.47% 7.35% 5.98% 5.21% 4.81%
Europe
3.31B 3.45B 3.36B 3.28B 3.27B 3.11B 3.06B 3.02B
Europe Growth
1.34% 11.09% 9.68% 8.30% 13.50% 14.91% 17.34% 26.21%
Other
958.10M 881.30M 846.30M 798.40M 759.30M 719.80M 667.10M 652.50M
Other Growth
26.18% 22.44% 26.86% 22.36% 28.11% 36.87% 45.31% 65.90%
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Acquired In-Process Research and Development
4.57B 4.63B 4.56B 4.60B 256.80M 527.10M 531.90M 509.20M
Acquired In-Process Research and Development Growth
1,680.14% 778.09% 757.06% 802.47% -44.25% 356.36% 140.57% 132.72%
Research and Development
3.82B 3.63B 3.46B 3.39B 3.21B 3.16B 3.03B 2.87B
Research and Development Growth
19.05% 14.78% 13.98% 18.24% 19.67% 24.51% 25.71% 28.34%
Selling, General, and Administrative
1.52B 1.46B 1.46B 1.35B 1.24B 1.14B 1.03B 1.02B
Selling, General, and Administrative Growth
22.60% 28.83% 40.67% 32.41% 27.57% 20.31% 3.96% 7.50%
Change in Value of Contingent Consideration
1.80M -500.00K -49.60M -48.70M -49.80M -51.60M 500.00K -3.30M
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.